Related Experiment Video
Updated: Jun 29, 2025
A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
Published on: July 10, 2018
Preclinical characterization of Pan-NKG2D ligand-binding NKG2D receptor decoys
Peter B Rupert1, Matthew Buerger1, Emily J Girard2
1Division of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Abstract:
NKG2D and its ligands are critical regulators of protective immune responses controlling infections and cancer, defining a crucial immune signaling axis. Current therapeutic efforts targeting this axis almost exclusively aim at enhancing NKG2D-mediated effector functions. However, this axis can drive disease processes when dysregulated, in particular, driving stem-like cancer cell reprogramming and tumorigenesis through receptor/ligand self-stimulation on tumor cells. Despite complexities with its structure and biology, we developed multiple novel engineered proteins that functionally serve as axis-blocking NKG2D "decoys" and report biochemical, structural, in vitro, and in vivo evaluation of their functionality.
Insights
Researchers developed novel NKG2D "decoy" proteins to block a key immune signaling axis implicated in cancer progression. These engineered decoys offer a new therapeutic strategy by inhibiting self-stimulating tumor cell pathways.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- The NKG2D/ligand axis is vital for immune responses against infections and cancer.
- Current therapies focus on enhancing NKG2D function, but dysregulation can promote cancer.
- Tumor cell self-stimulation via this axis drives stem-like reprogramming and tumorigenesis.
Purpose of the Study:
- To develop novel engineered proteins acting as NKG2D "decoys".
- To functionally block the NKG2D/ligand axis, particularly in disease-driving contexts.
- To evaluate the biochemical, structural, and functional properties of these decoy proteins.
Main Methods:
- Protein engineering of novel NKG2D decoy molecules.
- Biochemical assays to assess binding and blocking activities.
- Structural biology studies to understand protein interactions.
- In vitro and in vivo experiments to evaluate functional efficacy.
Main Results:
- Successful development of multiple engineered NKG2D decoy proteins.
- Demonstration of functional axis-blocking capabilities.
- Biochemical and structural characterization of the decoys.
- Validation of efficacy in relevant in vitro and in vivo models.
Conclusions:
- Engineered NKG2D decoys represent a promising therapeutic strategy.
- These decoys can inhibit dysregulated NKG2D/ligand axis activity in cancer.
- This approach offers a novel way to target cancer stem cell reprogramming and tumorigenesis.
More Related Videos
06:01Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
Published on: January 7, 2019
10:16Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets
Published on: March 12, 2019